Characterization of p53 in Chinese hamster cell lines CHO-K1, CHO-WBL, and CHL: Implications for genotoxicity testing

Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis

Volumn 426, Issue 1, 1999, Pages 51-62

  Hu, Ting ^a   Miller, Cathy M ^a   Ridder, Gregg M ^a   Aardema, Marilyn J ^a  

^a PROCTER AND GAMBLE COMPANY   (United States)

Author keywords

Cell cycle; Chinese hamster cell; DNA sequence; Mutation; p53; Protein expression

Indexed keywords

PROTEIN P53;

ANIMAL CELL; ARTICLE; CELL CYCLE; CHO CELL; CONTROLLED STUDY; DNA DAMAGE; DNA SEQUENCE; FEMALE; GENOTOXICITY; IMMUNOPRECIPITATION; LUNG ALVEOLUS CELL; MUTAGEN TESTING; MUTANT; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; SEQUENCE ANALYSIS; X IRRADIATION;

ANIMALS; BASE SEQUENCE; CELL CYCLE; CELL LINE; CHO CELLS; CRICETINAE; CRICETULUS; DNA PRIMERS; GENES, P53; MUTAGENICITY TESTS; PRECIPITIN TESTS; TUMOR SUPPRESSOR PROTEIN P53;

CRICETINAE; CRICETULUS GRISEUS;

EID: 0032965702     PISSN: 00275107     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0027-5107(99)00077-9     Document Type: Article

References (35)

1. Levine A.J., Perry M.E., Chang A., Silver A., Dittmer D., Wu M., Welsh D. The 1993 Walter Hubert Lecture: the role of the p53 tumor-suppressor gene in tumorigenesis. Br. J. Cancer. 69:1994;409-416.
2. Hollstein M., Shomer B., Greenblatt M., Soussi T., Hovig E., Montesano R., Harris C.C. Somatic point mutations in the p53 gene of human tumors and cell lines: updated compilation. Nucleic Acids Res. 24:1996;141-146.
3. Lane D.P. Cancer. p53, guardian of the genome. Nature. 358:1992;15-16.
4. Livingstone L.R., White A., Sprouse J., Livanos E., Jacks T., Tlsty T.D. Altered cell cycle arrest and gene amplification potential accompany loss of wild-type p53. Cell. 70:1992;923-935.
5. Yin Y., Tainsky M.A., Bishoff F.Z., Strong L.C., Wahl G.M. Wild-type p53 restores cell cycle control and inhibits gene amplification in cells with mutant p53 alleles. Cell. 70:1992;937-948.
6. Agapova L.S., Ilyinskaya G.V., Turovets N.A., Ivanov A.V., Chumakov P.M., Kopnin B.P. Chromosome changes caused by alterations of p53 expression. Mutat. Res. 354:1996;129-138.
7. Smith M.L., Fornace A.J. Jr. Genomic instability and the role of p53 mutations in cancer cells. Curr. Opin. Oncol. 7:1995;69-75.
8. Chaung W., Mi L.J., Boorstein R.J. The p53 status of Chinese hamster V79 cells frequently used for studies on DNA damage and DNA repair. Nucleic Acids Res. 25:1997;992-994.
9. Lee H., Larner J.M., Hamlin J.L. Cloning and characterization of Chinese hamster p53 cDNA. Gene. 184:1997;177-183.
10. Moro F., Ottaggio L., Bonatti S., Simili M., Miele M., Bozzo S., Abbondandolo A. p53 Expression in normal versus transformed mammalian cells. Carcinogenesis. 16:1995;2435-2440.
11. ± cell line is heterozygous for codon 170 mutation in the p53 tumor suppressor gene. Mutat. Res. 373:1997;157-165.
12. ± 3.7.2C mouse lymphoma cells. Mutagenesis. 13:1998;427-434.
13. ± human lymphoblastoid cells. Mutat. Res. 356:1996;129-134.
14. Little J.B., Nagasawa H., Keng P.C., Yu Y., Li C.Y. Absence of radiation-induced G1 arrest in two closely related human lymphoblast cell lines that differ in p53 status. J. Biol. Chem. 270:1995;11033-11036.
15. Hu T., Aardema M.J. Chinese hamster ovary (CHO) cells but not Chinese hamster lung cells (CHL) have a mutant p53 tumor suppressor gene in exon 6. Environ. Mol. Mutagen. 31:1998;65.
16. A Kerckaert G., Isofort R.J., Carr G.J., Aardema M.J., LeBoeuf R.A. A comprehensive protocol for conducting the Syrian hamster embryo cell transformation assay at pH 6.70. Mutat. Res. 356:1996;65-84.
17. Stephen C.W., Lane D.P. Mutant conformation of p53. Precise epitope mapping using filamentous phage epitope libray. J. Mol. Biol. 225:1992;577-583.
18. Rainaldi G., Marchetti S., Capacchi B., Meneveri R., Piras A., Leuzzi R. Absence of mutations in the highest mutability region of the p53 gene in tumor-derived CHEF 18 Chinese hamster cells. Mutagenesis. 13:1998;153-155.
19. Lutzker S.G., Levine A.J. A functionally inactive p53 protein in teratocarcinoma cells is activated by either DNA damage or cellular differentiation. Nat. Med. 2:1996;804-810.
20. Harris N., Brill E., Shohat O., Prokocimer M., Wolf D., Arai N., Rotter V. Molecular basis for heterogenecity of the human p53 protein. Mol. Cell. Biol. 6:1986;4650-4656.
21. Ullrich S.J., Mercer W.E., Appella E. Human wild-type p53 adopts a unique conformational and phosphorylation state in vivo during growth arrest of glioblastoma cells. Oncogene. 7:1992;1635-1643.
22. Pellegata N.S., Antoniono R.J., Redpath J.L., Stanbridge E.J. DNA damage and p53-mediated cell cycle arrest: a reevaluation. Proc. Natl. Acad. Sci. USA. 93:1996;15209-15214.
23. Kastan M.B., Onyekwere O., Sidransky D., Vogelstein B., Craig R.W. Participation of p53 protein in the cellular response to DNA damage. Cancer Res. 51:1991;6304-6311.
24. ± human lymphoblastoid cells. Mutat. Res. 357:1996;143-165.
25. Blagosklonny M.V. Loss of function and p53 protein stabilization. Hum. Pathol. 29:1998;613-619.
26. Paulovich A.G., Toczyski D.P., Hartwell L.H. When checkpoints fail. Cell. 88:1997;315-321.
27. Honma M., Hayashi M., Sofuni T. Cytotoxic and mutagenic responses to X-rays and chemical mutagens in normal and p53-mutant human lymphoblastoid cells. Mutat. Res. 374:1997;89-98.
28. Greenwood S.K., Armstrong M.J., Hill R.B., I Bradt C., Johnson T.E., Hilliard C.A., Galloway S.M. Fewer chromosome aberrations and earlier apoptosis induced by alkylating agents in human cells with normal compared with mutant p53. Mutat. Res. 401:1998;39-53.
29. M. Ishidate Jr., Data book of chromosomal abberration test in vitro, Elsevier, Biomedical Division, 1988, pp. 17-18.
30. Xia F., Wang X., Wang Y.H., Tsang N.M., Yandell D.W., Kelsey K.T., Liber H.L. Altered p53 status correlates with differences in sensitivity to radiation-induced mutation and apoptosis in two closely related human lymphoblast lines. Cancer Res. 55:1995;12-15.
31. Schwartz J.L., Jordan R., Sedita B.A., Swenningson M.J., P Banath J., Olive P.L. Different sensitivity to cell killing and chromosome mutation induction by gamma rays in two human lymphoblastoid cell lines derived from a single donor: possible role of apoptosis. Mutagenesis. 10:1995;227-233.
32. Donner E.M., Preston R.J. The relationship between p53 status, DNA repair and chromatid aberration induction in G2 mouse embryo fibroblast cells treated with bleomycin. Carcinogenesis. 17:1996;1161-1165.
33. Gupta N., Vij R., Haas-Kogan D.A., Israel M.A., Deen D.F., Morgan W.F. Cytogenetic damage and the radiation-induced G1-phase checkpoint. Radiat. Res. 145:1996;289-298.
34. Sofuni T., Matsuoka A., Sawada M., Ishidate M. Jr., Zeiger E., Shelby M.D. A comparison of chromosome abberration induction by 25 compounds tested by two Chinese hamster cell (CHL and CHO) systems in culture. Mutat. Res. 241:1990;173-213.
35. Galloway S.M., Sofuni T., Shelby M.D., Thilager A., Kumaroo V., Kaur P., Gulati D., Putman D.L., Murli H., Marshall R., Tanaka N., Anderson B., Zeiger E., Ishidate M. Jr. Multilaboratory comparison of in vitro tests for chromosome aberrations in CHO and CHL cells tested under the same protocols. Environ. Mol. Mutagen. 29:1997;189-207.